Author

E. Fiorito

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cell signaling & trafficking· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Hurtado-Rodriguez· 1 shared A. Repetto· 1 shared A. Wiedlocha· 1 shared A.-L. Borresen-Dale· 1 shared A.-M. Fosdahl· 1 shared E. M. Haugsten· 1 shared G. A. de Souza· 1 shared G. Tjonnfjord· 1 shared

Activity by Year

2017-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Hurtado-Rodriguez

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

NNV024, a novel humanized anti-CD37 antibody with enhanced ADCC and prolonged plasma half-life in human FcRn transgenic mice for treatment of NHL

R. Generaloc, E. Fiorito, S. Foss, V. Pascal, H. Heyerdahl, A. Repetto, J. T. Andersen, G. Tjonnfjord, S. S. Skanland, J. Dahle

This paper develops NNV024, a humanized anti-CD37 antibody with enhanced ADCC and prolonged plasma half-life, showing improved efficacy against NHL and CLL cells compared to existing therapies.

bioRxiv · Jul 12, 2023 · PreprintCancer Biology

Breast tumors escape endocrine therapy by ER-independent mechanisms triggered by the coordinated activities of HER2/HER3 and deacetylated FOXA1

S. Gilfillan, S. Wang, M. R. Katika, J. H. Norum, H. Bergholtz, E. Fiorito, S. Nordhagen, Y. Sharma, S. Singh, V. S. Somisety, A.-M. Fosdahl, S. Nord, O. Engebraaten, O. C. Lingjaerde, A.-L. Borresen-Dale, , A. Hurtado-Rodriguez

This study shows that HER2/HER3 signaling and FOXA1 deacetylation drive ER-independent growth in hormone-resistant breast tumors by altering FOXA1 chromatin binding and function.

bioRxiv · Sep 22, 2020 · PreprintCancer Biology

The phosphatase PTPRG controls FGFR1 activity and influences sensitivity to FGFR kinase inhibitors

J. Wesche, M. Kostas, E. M. Haugsten, Y. Zhen, V. Sorensen, P. Szybowska, E. Fiorito, S. Lorenz, G. A. de Souza, A. Wiedlocha

The paper identifies PTPRG as a phosphatase that dephosphorylates FGFR1, enhancing FGFR inhibitor sensitivity in osteosarcoma cells.

bioRxiv · Mar 24, 2017Cell Biology